[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Muller M, Dupre PF, Lucas B, Simon H, Malhaire JP, Guillemet C, Dessogne P, Pradier O: [Carcinosarcoma of the ovary]. J Gynecol Obstet Biol Reprod (Paris); 2007 Jun;36(4):399-402
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinosarcoma of the ovary].
  • Ovarian carcinosarcoma, also called malignant mixed mesodermal tumour, is a rare ovarian tumour representing less than two per cent of ovarian cancers.
  • Carcinosarcoma is an aggressive tumour, which associates some epithelial elements (carcinoma) with a stromal component (sarcoma).
  • There is no existing consensus concerning treatment.
  • Nevertheless, surgical treatment is paramount for the survival of patients.
  • Response rates to chemotherapy are about 20%.
  • [MeSH-major] Carcinosarcoma / diagnosis. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408876.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer; 2002 Mar 15;94(6):1739-46
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.
  • BACKGROUND: The purpose of this study was to reveal the clinical characteristics of nonleukemic granulocytic sarcoma (GS) and an association between the therapeutic regimens and the nonleukemic period.
  • These patients were divided into 3 groups by therapeutic regimens; Group I included 12 patients who received only biopsy or surgical resection of the tumor, Group II was 20 patients who received local irradiation for the tumor, and Group III consisted of 42 patients who received systemic chemotherapy.
  • In Group III, the period in the patients who were treated with chemotherapy given to ANLL was compared with that in the patients who received chemotherapy used for malignant lymphoproliferative disorders (MLPDs).
  • Preferential sites of GS were the small intestine, mediastinum, epidural site, uterus, and ovary, which often are difficult for the detection and diagnosis in addition to the skin and lymph nodes known commonly.
  • The nonleukemic period after the diagnosis of GS was significantly longer in Group III than in the other groups (median, 12 months in Group III vs. 3 and 6 months in Groups I and II, respectively).
  • The aggressive chemotherapy given to ANLL led to a longer nonleukemic period than the chemotherapy used for MLPDs.
  • CONCLUSIONS: To reduce the risk of subsequent ANLL in patients with nonleukemic GS, it is important that accurate histologic diagnosis is established initially for GS and that all isolated cases of GS, even those that appear to be cured by resection or irradiation of the tumor, are treated with intensive chemotherapy similar to that used to treat ANLL during the nonleukemic period as soon as possible.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Lymphoma / diagnosis. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920536.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


3. Olszewski U, Poulsen TT, Ulsperger E, Poulsen HS, Geissler K, Hamilton G: In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin Pharmacol; 2010;2:177-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study investigated the potential of DCA to increase the antitumor effects of platinum- based compounds against a panel of permanent cell lines, including small cell lung cancer (SCLC), ovarian cancer, and Ewing's sarcoma in vitro.
  • Additionally, cells were pretreated with DCA and then exposed to the platinum drugs and etoposide, or incubated with cisplatin or etoposide followed by application of DCA, respectively.
  • RESULTS: DCA 10 mM significantly increased the cytotoxicity of the platinum-based drugs carboplatin, satraplatin, JM118, and oxoplatin, but not cisplatin, picoplatin, and oxaliplatin in vitro.
  • CONCLUSION: DCA alone in a concentration that shows low antiproliferative activity is capable of increasing the cytotoxicity of selected platinum compounds upon coincubation, and such combinations may be interesting for clinical application in tumors like SCLC, Ewing's sarcoma, and ovarian cancer refractory to cisplatin chemotherapy as standard care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22291503.001).
  • [ISSN] 1179-1438
  • [Journal-full-title] Clinical pharmacology : advances and applications
  • [ISO-abbreviation] Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3262384
  • [Keywords] NOTNLM ; apoptosis / cytotoxicity / dichloroacetate / glycolysis / platinum
  •  go-up   go-down


Advertisement
4. Berkenblit A, Eder JP Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, Dahl TA, Dezube BJ, Supko JG: Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res; 2007 Jan 15;13(2 Pt 1):584-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: STA-4783 is a new compound that markedly enhances the therapeutic index of paclitaxel against human tumor xenograft models.
  • Partial responses were achieved in one patient with Kaposi's sarcoma and another with ovarian cancer that progressed during prior treatment with paclitaxel.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Synergism. Hydrazines / administration & dosage. Neoplasms / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Models, Chemical. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255281.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydrazines; 6UK191M53P / elesclomol; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Krawczuk-Rybak M, Leszczyńska E, Wysocka J, Zelazowska-Rutkowska B: [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer]. Pediatr Endocrinol Diabetes Metab; 2008;14(2):99-103
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer].
  • INTRODUCTION: Composed anticancer treatment leads to different late effects, such as ovarian failure, causing infertility or premature menopause.
  • AIM OF THE STUDY: was to analyse ovarian function, particularly anti-mullerian hormone levels, in young females after anticancer treatment.
  • PATIENTS AND METHODS: We analysed FSH, LH, estradiol and anti-mullerian hormone (AMH) levels on days 3-5 of a menstrual cycle in thirty three cancer survivors in mean age 19.1+/-4.7 years treated in age 12.0+/-5.6 years for Hodgkin Lymphoma (HL) (n=16), nephroblastoma (n=7), soft tissue sarcoma (n=4), germinal tumor (n=3), neuroblastoma (n=2), histiocytosis (n=1).
  • Particular analysis of all cases showed higher (>2 SD) FSH levels in 8 patients: 5 patients treated for HL with radiotherapy and higher total doses of procarbazine, nitrogen mustard and vinblastine; 2 patients treated for soft tissue sarcoma and one patient for Wilms tumor (all received radiotherapy).
  • Lowered AMH levels were found in 8 patients treated with chemo- and radiotherapy (4 - for HL, 2 - for Wilms tumor and 2 - for soft tissue sarcoma).
  • CONCLUSION: Composed anticancer treatment, especially radiotherapy, leads to ovarian failure.
  • Decreased AMH values at young adulthood suggest a lower ovarian reserve.
  • All causes and first symptoms of ovary damage should be known to the doctors who take care of the patients after anticancer treatment.
  • [MeSH-major] Anti-Mullerian Hormone / metabolism. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Infertility, Female / diagnosis. Menopause, Premature. Primary Ovarian Insufficiency / diagnosis. Radiotherapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy / adverse effects. Female. Follicle Stimulating Hormone / metabolism. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Neoplasms / therapy. Ovary / drug effects. Ovary / radiation effects. Survivors


6. Bolaman Z, Kadikoylu G, Kafkas S, Kacar F: Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism. Leuk Lymphoma; 2004 Jun;45(6):1285-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism.
  • Granulocytic sarcomas are extramedullary tumors (EMD) of malignant myeloid precursor cells.
  • EMD or granulocytic sarcoma of ovary is rare disease.
  • An inguinal mass (diameter 9.5 x 7.6) cm was detected on computed tomography.
  • The histopathological diagnosis of this was obtained from laporascopy was composed of ovotestis and there was marked blastic infiltration in this ovotestis which had myeloid markers on flow cytometry.
  • No response was achieved with combination chemotherapy and the patient died from progressive leukemia.
  • [MeSH-major] Disorders of Sex Development / complications. Myelodysplastic Syndromes / complications. Ovarian Neoplasms / pathology. Sarcoma, Myeloid / pathology. Testicular Neoplasms / pathology


7. Jones K: MEN-10755. Menarini. Curr Opin Investig Drugs; 2003 Dec;4(12):1473-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Menarini is developing the anthracycline aminodisaccharide MEN-10755 for the potential treatment of solid tumors.
  • Six phase II trials began in 2000 to verify the therapeutic activity of the drug in a variety of tumors, including sarcoma and those of the ovary, breast, prostate and lung.
  • [MeSH-major] Disaccharides / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Drugs, Investigational / therapeutic use. Neoplasms / drug therapy. Topoisomerase II Inhibitors
  • [MeSH-minor] Animals. Clinical Trials as Topic / statistics & numerical data. DNA Topoisomerases, Type II / metabolism. Enzyme Inhibitors / chemistry. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Humans. Technology, Pharmaceutical / methods

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14763135.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Disaccharides; 0 / Drugs, Investigational; 0 / Enzyme Inhibitors; 0 / Topoisomerase II Inhibitors; 80168379AG / Doxorubicin; EC 5.99.1.3 / DNA Topoisomerases, Type II; XS499WOZ93 / sabarubicin
  • [Number-of-references] 24
  •  go-up   go-down


8. Arbiser JL, Kau T, Konar M, Narra K, Ramchandran R, Summers SA, Vlahos CJ, Ye K, Perry BN, Matter W, Fischl A, Cook J, Silver PA, Bain J, Cohen P, Whitmire D, Furness S, Govindarajan B, Bowen JP: Solenopsin, the alkaloidal component of the fire ant (Solenopsis invicta), is a naturally occurring inhibitor of phosphatidylinositol-3-kinase signaling and angiogenesis. Blood; 2007 Jan 15;109(2):560-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PI3K and Akt are amplified or overexpressed in a number of malignancies, including sarcomas, ovarian cancer, multiple myeloma, and melanoma.
  • This pathway regulates production of the potent angiogenic factor vascular endothelial growth factor (VEGF), and protects tumor cells against both chemotherapy and reactive oxygen-induced apoptosis through phosphorylation of substrates such as apoptotic peptidase-activating factor-1 (APAF-1), forkhead proteins, and caspase 9.
  • Given its diverse actions, compounds that suppress the PI3K/Akt pathway have potential pharmacologic utility as angiogenesis inhibitors and antineoplastic agents.
  • [MeSH-major] Alkaloids / pharmacology. Neovascularization, Physiologic / drug effects. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein Kinase Inhibitors / pharmacology. Signal Transduction / drug effects
  • [MeSH-minor] Animals. Ants. Cell Line. Embryo, Nonmammalian / blood supply. Embryo, Nonmammalian / drug effects. Endothelial Cells / drug effects. Enzyme Activation / drug effects. Mice. Molecular Structure. Protein Kinases / chemistry. Protein Kinases / drug effects. Protein Kinases / metabolism. Zebrafish / embryology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35501-7 [12816951.001]
  • [Cites] Biochem J. 2003 Apr 1;371(Pt 1):199-204 [12534346.001]
  • [Cites] Protein Expr Purif. 2004 Jun;35(2):218-24 [15135396.001]
  • [Cites] N Engl J Med. 1990 Aug 16;323(7):462-6 [2197555.001]
  • [Cites] Science. 1991 Oct 11;254(5029):274-7 [1833819.001]
  • [Cites] Dev Dyn. 1995 Jul;203(3):253-310 [8589427.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):154-61 [8995241.001]
  • [Cites] Nature. 1997 Feb 6;385(6616):544-8 [9020362.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):861-6 [9023347.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1595-606 [9032287.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11345-50 [9326612.001]
  • [Cites] Biochem Biophys Res Commun. 1998 May 8;246(1):76-81 [9600071.001]
  • [Cites] Biochem J. 1998 Oct 1;335 ( Pt 1):1-13 [9742206.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4646-53 [9788617.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14950-5 [9843996.001]
  • [Cites] Curr Biol. 1999 Apr 22;9(8):433-6 [10226029.001]
  • [Cites] J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):925-9 [10365923.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2869-74 [10383148.001]
  • [Cites] Ann Intern Med. 1999 Sep 21;131(6):424-9 [10498558.001]
  • [Cites] Anal Biochem. 2005 Mar 1;338(1):136-42 [15707944.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):569-75 [16034524.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):713-22 [16546986.001]
  • [Cites] Diabetologia. 2006 Jul;49(7):1656-60 [16752184.001]
  • [Cites] Invest New Drugs. 2006 Sep;24(5):435-9 [16528479.001]
  • [Cites] Mol Med. 1998 Jun;4(6):376-83 [10780880.001]
  • [Cites] Org Lett. 2000 Jan 27;2(2):155-8 [10814270.001]
  • [Cites] Am J Pathol. 2000 Dec;157(6):1937-45 [11106566.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):79-82 [11147680.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):95-105 [10998351.001]
  • [Cites] J Org Chem. 2001 Mar 23;66(6):2181-2 [11300923.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):257-67 [12086862.001]
  • [Cites] Dev Biol. 2002 Aug 15;248(2):307-18 [12167406.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7335-42 [12499277.001]
  • [Cites] Methods Mol Med. 2003;83:127-36 [12619724.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1093-103 [14617782.001]
  • (PMID = 16990598.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127084348; United States / NCI NIH HHS / CA / K22 CA095325-02; United States / NIAMS NIH HHS / AR / R01 AR47901; United States / NCI NIH HHS / CA / K22 CA095325-01; United States / NCI NIH HHS / CA / K22 CA095325; United States / NIAMS NIH HHS / AR / R01 AR047901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Protein Kinase Inhibitors; 35285-25-7 / Solenopsin A; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC1785094
  •  go-up   go-down


9. Gari A, Souhami L, Arseneau J, Stanimir G: Primary malignant mesodermal ovarian sarcomas. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):106-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant mesodermal ovarian sarcomas.
  • Primary malignant mesodermal ovarian sarcomas are rare tumors and have a poor prognosis.
  • Most patients are treated with debulking surgery followed by adjuvant chemotherapy.
  • All patients underwent surgery and 90% received adjuvant chemotherapy.
  • Newer treatment strategies are urgently needed in the management of this disease.
  • [MeSH-major] Cause of Death. Mixed Tumor, Mesodermal / mortality. Mixed Tumor, Mesodermal / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Prognosis. Risk Assessment. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445619.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Ateser G, Yildiz O, Leblebici C, Mandel NM, Unal F, Turna H, Arikan I, Colcaki D: Metastatic primitive neuroectodermal tumor of the ovary in pregnancy. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):266-9
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic primitive neuroectodermal tumor of the ovary in pregnancy.
  • Primitive neuroectodermal tumor (PNET) is a small round tumor belonging to the PNET/Ewing's sarcoma family.
  • We hereby report a case of PNET of the ovary, which was detected at the second trimester of pregnancy.
  • Chemotherapy was administered and a healthy baby was delivered by cesarean section.
  • Chemotherapy was continued, but she died due to progressive disease 13 months after the initial diagnosis.
  • In this case report, we discuss chemotherapy options during pregnancy and the importance of multidisciplinary approach to unusual presentations of rare tumors.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / drug therapy. Pregnancy Complications, Neoplastic / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291265.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Carter NJ, Keam SJ: Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs; 2010 Feb 12;70(3):355-76
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
  • It is indicated in the EU and many other countries for use in patients with advanced soft-tissue sarcoma (STS) who have progressed despite receiving previous treatment with anthracyclines and ifosfamide or in those who are unable to receive these agents.
  • It is also approved in the EU in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer.
  • In addition, trabectedin holds orphan drug status for the treatment of advanced, recurrent STS in the US, Switzerland and Korea, and for the treatment of advanced, recurrent ovarian cancer in the US and Switzerland.
  • Clinical trials showed that intravenous trabectedin was effective in chemotherapy-experienced patients with advanced, recurrent liposarcoma or leiomyosarcoma, and results from a retrospective analysis suggest that the drug may be particularly effective in patients with advanced myxoid liposarcoma.
  • In addition, coadministration of trabectedin with pegylated liposomal doxorubicin was associated with a significantly longer progression-free survival (6 weeks) than pegylated liposomal doxorubicin monotherapy in patients with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy.
  • Results to date indicate that trabectedin is a valuable addition to the group of second-line antineoplastic agents available for the treatment of advanced, recurrent STS, and that it is a beneficial treatment for recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy when administered in conjunction with pegylated liposomal doxorubicin.
  • [MeSH-major] Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dioxoles. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tetrahydroisoquinolines

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4188-96 [19652065.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Dec;63(1):181-8 [18379785.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14 (20):6449-55 [18927284.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8155-62 [16912194.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10 ):1484-90 [16737808.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):3-14 [16379042.001]
  • [Cites] Drugs. 2002;62(8):1185-92; discussion 1193-4 [12010079.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Apr 1;228(1):17-23 [18191164.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):449-57 [19190116.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5484-92 [16110008.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7 [15701855.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14 (20):6656-62 [18927308.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):811-5 [16096428.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12 ):2305-11 [14676811.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2964-71 [15805300.001]
  • [Cites] J Clin Oncol. 2010 Jul 1;28(19):3107-14 [20516432.001]
  • [Cites] Clin Pharmacol Ther. 2008 Jan;83(1):130-43 [17597713.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5902-8 [14522916.001]
  • [Cites] Mol Biol Cell. 2008 Sep;19(9):3969-81 [18632984.001]
  • [Cites] Am J Clin Dermatol. 2008;9(4):207-17 [18572972.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12 ):1618-24 [18000504.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jun;62(1):135-47 [17922277.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1705-10 [10674017.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3377-81 [12067978.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13062-7 [17656556.001]
  • [Cites] Drugs. 2007;67(15):2257-76 [17927287.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10 ):1802-9 [18497430.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):825-37 [16988825.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):609-18 [18243687.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]
  • [Cites] Invest New Drugs. 2010 Apr;28(2):145-55 [19238326.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):401-10 [17442231.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Dec;8(8):886-903 [19075571.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Eur J Cancer. 2008 Aug;44(12 ):1726-33 [18501589.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):565-7 [17613417.001]
  • [Cites] Ann Oncol. 2009 Nov;20(11):1794-802 [19556318.001]
  • [Cites] Eur J Cancer. 2009 Aug;45(12 ):2116-22 [19419856.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Curr Clin Pharmacol. 2009 Jan;4(1):38-42 [19149499.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S70-2 [18813266.001]
  • [Cites] Biochem Pharmacol. 2009 May 15;77(10 ):1642-54 [19426702.001]
  • [Cites] Clin Pharmacokinet. 2007;46(10 ):867-84 [17854236.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1309-18 [18483318.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1867-74 [15774779.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1153-61 [19114300.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Ann Oncol. 2009 Aug;20(8):1439-44 [19465423.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):935-43 [16162970.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12 ):4725-32 [11156226.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii89-93 [18456783.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6(8):766-94 [18926089.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1609-18 [18518789.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Nat Prod Rep. 2009 Mar;26(3):322-37 [19240944.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii14-6 [18456751.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]
  • (PMID = 20166769.001).
  • [ISSN] 1179-1950
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  • [Number-of-references] 104
  •  go-up   go-down


12. Gupta D, Deavers MT, Silva EG, Malpica A: Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases. Am J Surg Pathol; 2004 Jun;28(6):771-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases.
  • Ovarian malignant melanoma (MM), primary or metastatic, is an extremely rare tumor and in the absence of a previous diagnosis can represent a diagnostic challenge.
  • A previous history of MM was definitively obtained in 14 patients; in these cases, the interval between the primary MM and the ovarian metastasis ranged from 15 to 228 months (mean 77.7 months).
  • The tumor cell type was epithelioid in 19 cases, spindled in 2 cases, mixed epithelioid and spindled in 1 case, and small cell in 1 case.
  • In 8 cases, initial diagnoses included sex cord stromal tumor, germ cell tumor, sarcoma, or undifferentiated carcinoma.
  • Treatment performed in 18 of the cases are as follows: oophorectomy with/without chemotherapy (10); total abdominal hysterectomy with bilateral salpingo-oophorectomy with/without chemotherapy (6); vaginal hysterectomy, bilateral salpingo-oophorectomy, and chemotherapy (1); and total abdominal hysterectomy with salpingo-oophorectomy (1).
  • In conclusion, MM involving the ovary is a rare disease, predominantly seen in women of reproductive age, and is associated with a poor prognosis.
  • Nodular or diffuse pattern and epithelioid cell type are most frequently seen, and the tumor can be mistaken for germ cell and sex cord stromal tumors.
  • [MeSH-major] Melanoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, Neoplasm. Calbindin 2. DNA-Binding Proteins / analysis. Ethnic Groups. Female. Humans. Hysterectomy. Immunohistochemistry. Inhibins / analysis. MART-1 Antigen. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor. Middle Aged. Monophenol Monooxygenase / analysis. Neoplasm Metastasis. Neoplasm Proteins / analysis. S100 Calcium Binding Protein G / analysis. S100 Proteins / analysis. Teratoma / pathology. Transcription Factors / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15166669.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / DNA-Binding Proteins; 0 / MART-1 Antigen; 0 / MITF protein, human; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Transcription Factors; 57285-09-3 / Inhibins; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


13. Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK: [Clinical review of 97 patients with endometrial stromal sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):115-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical review of 97 patients with endometrial stromal sarcoma].
  • OBJECTIVE: To review the survival outcomes in patients with endometrial stromal sarcoma (ESS) in Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, and to discuss prognostic factors and the role of post-operative adjuvant radiotherapy and chemotherapy.
  • The median age at diagnosis was 44.0 years.
  • The median follow-up time was 62 months (5 - 277 months).
  • The median time-to-recurrence (TTR) was 27 months.
  • The recurrence rates of the patients with or without preserve of ovary were 89% and 24%, respectively (P = 0.000).
  • The risk of recurrence of patients with preserve of ovary was remarkably higher than that of patients without preserve of ovary.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Sarcoma, Endometrial Stromal / pathology. Sarcoma, Endometrial Stromal / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovariectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683750.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Dilek TU, Dilek S, Pata O, Tataroglu C, Tok E: Malignant fibrous histiocytoma of the ovary: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:352-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the ovary: a case report.
  • Malignant fibrous histiocytoma is the most common type of soft tissue sarcoma in adults.
  • Primary malignant fibrous histiocytoma of the ovary is extremely rare, with only three previously reported cases.
  • She was referred for adjuvant chemotherapy to our center with the diagnosis of storiform-pleomorphic malignant fibrous histiocytoma.
  • A left adnexal mass was detected by computed tomography of the lower abdomen.
  • Resection of all macroscopic disease is independently associated with improved disease-specific survival, and adjuvant chemotherapy for nonmyxoid variants could be acceptable alternatives if the surgical margins are tumor free.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Female. Humans. Reoperation

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515621.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Kosmas C, Mylonakis N, Tsakonas G, Vorgias G, Pantelis N, Politis P, Kalinoglou N, Tsavaris N, Akrivos T, Karabelis A: Paclitaxel (T), ifosfamide (I), and carboplatin (Cb) (TICb) combination chemotherapy in advanced uterine and adnexal malignant mixed mullerian tumors (MMMTs). J Clin Oncol; 2009 May 20;27(15_suppl):5517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel (T), ifosfamide (I), and carboplatin (Cb) (TICb) combination chemotherapy in advanced uterine and adnexal malignant mixed mullerian tumors (MMMTs).
  • METHODS: Patients with advanced MMMTs [stages III-IV and relapses after surgery (Sx)±RT], WHO-PS 0-2, no prior chemotherapy, unimpaired hematopoietic/organ function were eligible.
  • Chemotherapy was administered as follows; T: 175 mg/m<sup>2</sup> d1, I: 2.0 g/m<sup>2</sup>/d-d1+2, and Cb at a target AUC = 5 (according to creatinine clearance based on Calvert's formula) on d2 after I.
  • RESULTS: Thirty-two patients with MMMTs of the uterus (n = 28), tubes (n = 2), or ovary (n = 2) have entered so far and all are evaluable for response and toxicity: median age = 61 (45-72), PS = 1 (0-1), stages; III = 18 (56%), IV = 14 (44%), histologies were; with homologous sarcoma component: 21, with heterologous component: 11.
  • Prior treatment for locoregional disease included Sx: 23, Sx+RT: 9.
  • Disease sites at diagnosis included: pelvic disease 12; pelvic/paraortic lymph nodes 14; peritoneal implants 16; liver 4; lung nodules 9; bone metastases 1; malignant pleural effusion 4.
  • Responses were as follows: 21/32 (66%) evaluable patients responded, with 9 complete responses (CR) and 12 partial responses (PR), while 8 had stable disease (SD), and 3 developed progressive disease (PD).
  • The median response duration was 8 mo (4-28), median time-to-progression (TTP) 12.5mo (4-26), while median overall survival (OS) has not been reached yet since most patients receive second-line therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962459.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Cioffi A, LeCesne A, Blay J, Delaloge S, Yovine A, Maki R, Nieto A, Jiao JJ, Demetri GD: Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its unique antitumor properties, attributed to specific binding to the small groove of DNA, have been demonstrated activity against soft-tissue sarcoma (STS), ovarian, breast and prostate cancer.
  • Trabectedin treatment has been authorized by EMEA for STS after failure of standard treatment and shows efficacy in relapsed ovarian cancer in a phase III study.
  • MedDRA and NCI-CTC v1.0/2.0 were used to code and grade treatment-emergent adverse events (AEs).
  • Diagnosis included sarcoma (56%), ovary (26%) and breast (7%) cancer, for which 90% of pts had received chemotherapy, 37.5% radiotherapy, and 96.0% surgery.
  • Fifteen drug-related deaths (1.3%) occurred.
  • CONCLUSIONS: Single-agent trabectedin was reasonably well tolerated, with low rates of drug-related discontinuations and deaths.
  • Sustained clinical benefit in the absence of relevant cumulative toxicities allows its administration to patients for prolonged periods of time.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ota S, Ushijima K, Fujiyoshi N, Fujimoto T, Hayashi R, Murakami F, Komai K, Fujiyoshi K, Hori D, Kamura T: Desmoplastic small round cell tumor in the ovary: Report of two cases and literature review. J Obstet Gynaecol Res; 2010 Apr;36(2):430-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round cell tumor in the ovary: Report of two cases and literature review.
  • We report two cases of DSRCT in young women that presented clinically as ovarian tumor with extensive pelvic and abdominal dissemination.
  • Both patients underwent debulking surgery and combined chemotherapy.
  • After primary therapy, the tumors recurred and both women died of the disease.
  • The clinical presentation and differential diagnosis, as well as the treatment, including surgical debulking and combined chemotherapy are discussed.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sarcoma, Small Cell / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Ovary / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492402.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


18. Lenhard SM, Untch M, Himsl I, Ditsch N, Bittmann I, Friese K, Bauerfeind I: The high-grade endometrial sarcoma: a rare entity. Arch Gynecol Obstet; 2006 Apr;274(1):56-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high-grade endometrial sarcoma: a rare entity.
  • INTRODUCTION: With an estimated incidence of one to two per one million women, the endometrial stromal sarcoma (ESS) is a rare disease.
  • It is subclassified into a high-grade and a prognostically better low-grade type.
  • Evidence-based data for a standardized therapy is lacking.
  • A fractioned curettage yielded a differential diagnosis of malignant muellerian mixed tumor or a non-differentiated endometrial sarcoma.
  • For completion of the operative treatment, laparotomy with hysterectomy, adnexectomy, and pelvine lymphonodectomy were performed.
  • The final histological report described a 7 cm non-differentiated endometrial sarcoma with infiltration of the left ovary and 25 tumor-free lymph nodes.
  • DISCUSSION: Standard therapy for resectable sarcoma is abdominal hysterectomy and bilateral adnexectomy.
  • So far, there is little data from studies reporting radio- or chemotherapy treatment of small patient numbers in an adjuvant setting.
  • Due to missing clinical data, it remains a multidisciplinary therapeutic challenge requiring individual decisions.
  • To receive more information on this rare disease, treatment should be performed according to international protocols.
  • [MeSH-major] Endometrial Neoplasms / pathology. Sarcoma, Endometrial Stromal / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Hysterectomy. Metrorrhagia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311750.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Kim KJ, Jang BW, Lee SK, Kim BK, Nam SL: A case of peripheral primitive neuroectodermal tumor of the ovary. Int J Gynecol Cancer; 2004 Mar-Apr;14(2):370-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of peripheral primitive neuroectodermal tumor of the ovary.
  • Peripheral primitive neuroectodermal tumor (PNET) belongs to the PNET/Ewing's sarcoma family.
  • PNET is a small round cell tumor of putative neuroectoderm origin and is the second most common sarcoma among children and young adults.
  • It may occur anywhere in the body and within any age group; however, it is most likely to occur in the bone and soft tissues.
  • There have been a small number of case reports of PNET arising in the ovary.
  • We presented a case of PNET arising in the right ovary of an 18-year-old woman.
  • We had persecuted Taxol/carboplatin chemotherapy, pelvic cavity radiotherapy, and Vincristine/Actinomycin, Cyclophosphamide/Doxorubicin (VACA).
  • [MeSH-major] Neuroectodermal Tumors / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15086740.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Carter NJ, Keam SJ: Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs; 2007;67(15):2257-76
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
  • Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents.
  • It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer.
  • In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer.
  • The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tetrahydroisoquinolines / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1998 Sep;9(9):981-7 [9818072.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):333-42 [15713904.001]
  • [Cites] J Med Chem. 2006 Nov 16;49(23 ):6925-9 [17154523.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8155-62 [16912194.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10 ):1484-90 [16737808.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):3-14 [16379042.001]
  • [Cites] Drugs. 2002;62(8):1185-92; discussion 1193-4 [12010079.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 15;66(12 ):2381-95 [14637196.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5484-92 [16110008.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):323-33 [15661559.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7 [15701855.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):811-5 [16096428.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12 ):2305-11 [14676811.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2964-71 [15805300.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5902-8 [14522916.001]
  • [Cites] Mol Pharmacol. 2005 Nov;68(5):1496-503 [15961672.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3893-903 [12473605.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1327-31 [15177491.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii74-6 [17491057.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3377-81 [12067978.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):1-7 [16633714.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15 [17512352.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):825-37 [16988825.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Clin Cancer Res. 2010 May 1;16(9):2656-65 [20406837.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1610-4 [16736024.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6 [16716798.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20 [17291226.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1605-16 [16273217.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii12-4 [17491026.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1867-74 [15774779.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):336-40 [17545796.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):935-43 [16162970.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12 ):4725-32 [11156226.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] Cancer. 2003 Aug 15;98 (4):832-40 [12910529.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]
  • (PMID = 17927287.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  • [Number-of-references] 80
  •  go-up   go-down


21. Foster R, Solano S, Mahoney J, Fuller A, Oliva E, Seiden MV: Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of c-KIT. Gynecol Oncol; 2006 May;101(2):363-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of minimal response to sarcoma directed chemotherapy, the possibility that the tumor was in fact an eGIST was investigated and supported by immunohistochemical and mutational analyses of the c-Kit receptor tyrosine kinase.
  • CONCLUSIONS: The possibility of eGIST should be considered in the differential diagnosis of tumors with a spindle cell morphology in the gynecologic tract especially when involving the ovary, fallopian tube, or uterine serosa.
  • [MeSH-minor] Base Sequence. Diagnosis, Differential. Female. Humans. Middle Aged. Molecular Sequence Data

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16439005.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


22. Sadzuka Y, Hatakeyama H, Sonobe T: Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment. Int J Pharm; 2010 Jan 4;383(1-2):186-91
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment.
  • Cucurbitacin E increases the doxorubicin (DOX) level in M5076 ovarian sarcoma via suppressed DOX efflux in vitro.
  • MK-571, a multidrug resistance associated protein (MRP) inhibitor, significantly suppressed DOX efflux from M5076 ovarian sarcoma cells.
  • The combination of cucurbitacin E with MK-571 also inhibited DOX efflux, whereas the efficacy was the same in each treatment.
  • The cucurbitacin E co-treatment significantly increased DOX concentration in the tumor within a short time after DOX administration, whereas the same treatment decreased the DOX concentration in normal tissues.
  • The different effects of cucurbitacin E between tumor and normal tissues was speculated to be related to differences in DOX transport system on cell membrane.
  • In DOX therapy, cucurbitacin E co-treatment was expected to increase DOX induced antitumor activity without an increase in adverse reactions due to DOX.
  • [MeSH-major] Doxorubicin / administration & dosage. Doxorubicin / metabolism. Ovarian Neoplasms / metabolism. Sarcoma / metabolism. Triterpenes / administration & dosage. Triterpenes / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Synergism. Drug Therapy, Combination. Female. Leukemia P388 / drug therapy. Leukemia P388 / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Inbred DBA. Propionates / pharmacology. Quinolines / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732815.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Propionates; 0 / Quinolines; 0 / Triterpenes; 18444-66-1 / cucurbitacin E; 5Q9O54P0H7 / verlukast; 80168379AG / Doxorubicin
  •  go-up   go-down


23. Sadzuka Y, Hatakeyama H, Daimon T, Sonobe T: Screening of biochemical modulator by tumor cell permeability of doxorubicin. Int J Pharm; 2008 Apr 16;354(1-2):63-9
Hazardous Substances Data Bank. CAPSAICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, the combination of cucurbitacin E and DOX showed increased cytotoxicity when compared to each treatment alone.
  • In vivo, DOX alone treatment did not change the time course of tumor size or tumor weight of M5076 ovarian sarcoma, compared to control levels.
  • In conclusion, the combination of cucurbitacin E with DOX may be an effective tool with treated application in the cancer chemotherapy.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacokinetics. Carcinoma, Ehrlich Tumor / drug therapy. Doxorubicin / pharmacokinetics. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Animals. Biological Transport / drug effects. Capsaicin / pharmacology. Catechols. Cell Line, Tumor. Coumaric Acids / pharmacology. Drug Screening Assays, Antitumor. Drug Synergism. Fatty Alcohols / pharmacology. Female. Male. Mice. Neoplasm Transplantation. Permeability / drug effects. Sarcoma / drug therapy. Triterpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. FERULIC ACID .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054183.001).
  • [ISSN] 0378-5173
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Catechols; 0 / Coumaric Acids; 0 / Fatty Alcohols; 0 / Triterpenes; 18444-66-1 / cucurbitacin E; 80168379AG / Doxorubicin; 925QK2Z900 / gingerol; AVM951ZWST / ferulic acid; S07O44R1ZM / Capsaicin
  •  go-up   go-down


24. Sugiyama T, Sadzuka Y: Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. Biochim Biophys Acta; 2003 Dec 5;1653(2):47-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biochemical modulation has played an important role in the development of cancer chemotherapy.
  • In M5076 ovarian sarcoma-bearing mice, theanine significantly enhanced the inhibitory effect of DOX on tumor growth and increased the DOX concentration in the tumor, compared to DOX-alone group.
  • Moreover, the combination of theanine with DOX suppressed the hepatic metastasis of ovarian sarcoma.
  • In contrast, an increase in DOX concentration was not observed in normal tissues, such as liver and heart.
  • Consequently, the modulating effect of theanine on the efficacy of antitumor agents is expected to be applicable in clinical cancer chemotherapy.
  • [MeSH-major] Amino Acid Transport System X-AG / antagonists & inhibitors. Antineoplastic Agents / therapeutic use. Doxorubicin / therapeutic use. Glutamates / pharmacology. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Drug Synergism. Enzyme Inhibitors / pharmacology. Humans. Mice

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. Theanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14643924.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amino Acid Transport System X-AG; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Glutamates; 80168379AG / Doxorubicin; 8021PR16QO / theanine
  • [Number-of-references] 66
  •  go-up   go-down


25. Gangadharan VP, Sasidharan K, Preetha S, Chithrathara K: Chronic systemic (hepatosplenic) candidiasis in a patient with granulocytic sarcoma. Am J Clin Oncol; 2000 Dec;23(6):562-3
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic systemic (hepatosplenic) candidiasis in a patient with granulocytic sarcoma.
  • We report a young woman who underwent extensive chemotherapy for granulocytic sarcoma of the ovary; CSC then developed in this patient.
  • Clinical presentation, diagnostic problems, and the current successful treatment with fluconazole and liposomal amphotericin B are discussed.
  • [MeSH-major] Candidiasis / complications. Liver Diseases / complications. Opportunistic Infections / complications. Ovarian Neoplasms / complications. Sarcoma / complications. Splenic Diseases / complications
  • [MeSH-minor] Adult. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chronic Disease. Female. Fluconazole / therapeutic use. Humans. Tomography, X-Ray Computed


26. Muggia FM: Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep; 2001 Mar;3(2):156-62
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal encapsulated anthracyclines: new therapeutic horizons.
  • Already, approved indications have been achieved for doxorubicin against Kaposi's sarcoma and ovarian cancers, and for daunorubicin against Kaposi's sarcoma.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Breast Neoplasms / drug therapy. Female. Humans. Leukemia / drug therapy. Liposomes. Lymphoma / drug therapy. Multiple Myeloma. Ovarian Neoplasms / drug therapy. Sarcoma, Kaposi / drug therapy

  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1964 Feb 15;201:706-7 [14142092.001]
  • [Cites] Cancer Chemother Rep. 1969 Feb;53(1):33-7 [5772652.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):996-1003 [7707129.001]
  • [Cites] Am J Obstet Gynecol. 1989 Apr;160(4):812-7; discussion 817-9 [2712114.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1093-100 [2348224.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3185-91 [9336354.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):40-6 [10607318.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3093-100 [10963637.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1425-34 [10334527.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] J Clin Pharmacol. 1996 Jan;36(1):55-63 [8932544.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3432-7 [10589755.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):987-93 [9060537.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):131-41 [10585596.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1037-47 [10964334.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4 Suppl 3):45-55 [6594763.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):691-5 [10942057.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1777-85 [7602367.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2349-51 [10829060.001]
  • [Cites] Cancer. 1967 Mar;20(3):333-53 [4290058.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1131-3 [9834828.001]
  • [Cites] Cancer Res. 1970 Oct;30(10):2572-82 [5474180.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 May;73(5):1603-7 [818640.001]
  • [Cites] Ann Oncol. 2000 Aug;11(8):1029-33 [11038041.001]
  • [Cites] Cancer Chemother Rep. 1970 Feb;54(1):1-7 [5527012.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1435-41 [10334528.001]
  • [Cites] Hematol Oncol. 1998 Jun;16(2):47-55 [10065112.001]
  • [Cites] J Nucl Med. 1983 Jan;24(1):45-51 [6848703.001]
  • [Cites] J Biol Response Mod. 1988 Aug;7(4):359-64 [3049944.001]
  • [Cites] Pathol Biol. 1967 Oct;15(19):921-4 [4869766.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10 [2231759.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):697-700 [10942058.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2353-64 [8708728.001]
  • [Cites] Cancer Treat Rev. 1993 Jul;19(3):197-228 [8334677.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2796-802 [8504422.001]
  • [Cites] Invest New Drugs. 1994;12(2):103-10 [7860226.001]
  • [Cites] Ann Intern Med. 1974 Feb;80(2):249-59 [4590654.001]
  • (PMID = 11177748.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR00096
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 80168379AG / Doxorubicin; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 51
  •  go-up   go-down


27. Polish Paediatric Solid Tumours Study Group, Bień E, Stachowicz-Stencel T, Kazanowska B, Balcerska A, Balwierz W, Chybicka A, Dłuzniewska A, Drozyńska E, Kurylak A, Matysiaks M, Krawczuk-Rybak M, Rychłowska M, Solarz E, Sopyło B, Stencels D, Wachowiaks J, Wieczorek M, Woźniak W, Wysocki M: [Genitourinary soft tissue sarcomas located outside bladder and prostate in children treated according to the CWS-96 protocol--report from the Polish Paediatric Solid Tumours Study Group]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):507-15
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genitourinary soft tissue sarcomas located outside bladder and prostate in children treated according to the CWS-96 protocol--report from the Polish Paediatric Solid Tumours Study Group].
  • AIM: Analysis of therapy efficacy in non-bladder/prostate genitourinary sarcomas in children treated from I'1997 to VI'2003 with CWS-96 protocol in Poland.
  • RESULTS: Primary site: testes - 9 patients, paratesticular region - 6, uterus - 2, vagina and ovary-1 of each.
  • Primary tumour exceeded 5cm and/or invaded surrounding tissues in 7 patients (37%).
  • Six of 7 patients with macroscopic tumour residues responded to chemotherapy (CR-4, GR-2).
  • Radiotherapy (23,5-54 Gy) was given to 8 patients.
  • 3 children developed local relapse, 3 patients died (16%): 2 due to neoplasm progression, 1 of neutropenia-related sepsis.
  • 1) prognosis in children with non-bladder/prostate genitourinary sarcomas is favourable despite incomplete primary excision of the neoplasm.
  • 2) chemotherapy and radiotherapy were accompanied by severe but transient myelosupression in the HR group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / drug therapy. Sarcoma / diagnosis. Sarcoma / drug therapy. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Lymphatic Metastasis. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719163.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Cribbs RK, Shehata BM, Ricketts RR: Primary ovarian rhabdomyosarcoma in children. Pediatr Surg Int; 2008 May;24(5):593-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian rhabdomyosarcoma in children.
  • Although rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, primary rhabdomyosarcomas of the ovary are extremely rare, with only eight well-documented pediatric cases previously reported in the literature.
  • We present two additional cases: an alveolar RMS originating in the right ovary with metastatic spread to the splenic flexure of the colon and to both lungs in a 13-year-old African American girl, and an embryonal RMS arising in the right ovary of a 6-year-old Caucasian girl with pre-operative intra-abdominal rupture and a malignant right pleural effusion.
  • Both patients had complete resection of their primary tumors and received chemotherapy including vincristine, doxorubicin and cyclophosphamide with good response to therapy.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Rhabdomyosarcoma / diagnosis
  • [MeSH-minor] Adolescent. Biopsy, Needle. Chemotherapy, Adjuvant. Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Ovariectomy / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] AMA Arch Pathol. 1959 Jul;68(1):74-82 [13660587.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17(2):113-9 [9553806.001]
  • [Cites] J Pathol Bacteriol. 1955 Oct;70(2):433-8 [13295919.001]
  • [Cites] Histopathology. 1989 Sep;15(3):309-11 [2807189.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):297-300 [6574802.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):899-904 [2545329.001]
  • [Cites] Gynecol Oncol. 1983 Jun;15(3):325-39 [6345285.001]
  • (PMID = 18004572.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Ozguroglu M, Bilici A, Ilvan S, Turna H, Atalay B, Mandel N, Sahinler I: Determining predominating histologic component in malignant mixed müllerian tumors: is it worth it? Int J Gynecol Cancer; 2008 Jul-Aug;18(4):809-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of MMMT derive from either ovary or uterus.
  • In our study, we investigated the role of carcinomatous and sarcomatous component on response to chemotherapy and disease outcome.
  • All the paraffin specimens were reevaluated according to the histopathologic features (primary site and percentages of carcinomatous and sarcomatous component) and the effect of predominant histologic type on response to treatment.
  • Primary tumor sites were ovary and endometrium in 36% and 64% of patients, respectively.
  • Ten of 25 patients (40%) were treated with a combination chemotherapy regimen of cisplatin-ifosfamide (PI) and 7 patients (28%) were treated with paclitaxel-carboplatin (PC) protocol.
  • Despite chemotherapy, 17.6% of patients had progressive disease.
  • The remaining 13 patients (54.2%) responded to chemotherapy.
  • Predominating histopathologic feature (carcinoma or sarcoma) should be taken into consideration in predicting the response and planning the chemotherapy regimen.
  • [MeSH-major] Mixed Tumor, Mullerian / diagnosis. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Planning Techniques. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892455.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, Faircloth GT: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer; 2003 Sep;39(13):1920-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Yondelis (trabectidin, ET-743) is a marine natural product that has shown activity both in preclinical systems and in human malignancies such as soft tissue sarcoma and ovarian cancers that are resistant to previous chemotherapies.
  • Molecular pharmacological studies indicated that Yondelis interacts with DNA and DNA repair systems in a way that is different from Cisplatin (DDP).
  • The in vitro studies performed in human TE-671 rhabdomyosarcoma, Igrov-1 and 1A9 human ovarian carcinoma cell lines showed additive effects or slight synergism.
  • Several human tumour xenografts, such as TE-671 rhabdomyosarcoma, SK-N-DX neuroblastoma, FADU head and neck, LX-1 non-small cell lung cancer (NSCLC), H-187 melanoma and SKOV HOC 8 ovarian carcinoma, showed an antitumour effect for the combination that was greater than that of each drug when given as a single agent.
  • An orthotopically transplanted human ovarian cancer HOC 8 growing in the peritoneal cavity of nude mice was used that is insensitive to Yondelis alone and only moderately sensitive to DDP alone.
  • The combination of the two drugs produced a dramatic increase of survival lasting several months.
  • In conclusion, the combination of Yondelis and DDP is synergistic in vivo (i.e. the antitumour effect is greater than that of each drug used as a single agent at the maximum tolerated dose (MTD)) in different human tumour xenografts.
  • The two drugs can be combined at the MTD of each drug, thus indicating there are no overlapping toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Animals. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dioxoles / administration & dosage. Dioxoles / adverse effects. Drug Synergism. Female. Humans. Isoquinolines / administration & dosage. Isoquinolines / adverse effects. Mice. Neoplasm Transplantation. Tetrahydroisoquinolines. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2003 Sep;39(13):1816-7 [12932657.001]
  • (PMID = 12932672.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


31. Panagiotou JP, Polychronopoulou S, Sofou K, Vanvliet-Constantinidou C, Papandreou E, Haidas S: Second and third malignant solid tumor in a girl with ovarian Sertoli-Leydig tumor. Pediatr Blood Cancer; 2006 May 1;46(5):654-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second and third malignant solid tumor in a girl with ovarian Sertoli-Leydig tumor.
  • We report a Sertoli-Leydig cell (SLC) tumor of the right ovary in a 10-year-old girl, which was dealt with surgical removal.
  • Chemotherapy, according to SIOP-? ? ?
  • Three years after completing treatment, the patient developed a painful swelling at her left upper arm.
  • The diagnosis was Ewing sarcoma of the humerus, which was confirmed by identification of the typical 11; 22 translocation on cytogenetic and molecular analysis of the tumor tissue.
  • The patient died 14 months from Ewing diagnosis due to progressive disease.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 22 / genetics. Fatal Outcome. Female. Humans. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16411221.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Misset JL: A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer; 2006 Jun 5;94(11):1610-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is currently under phase II/III development in breast cancer, hormone refractory prostate cancer, sarcomas and ovarian cancer.
  • The present study assessed the activity and feasibility of trabectedin in women with advanced breast cancer previously treated with conventional therapies.
  • Patients with advanced disease previously treated with at least one but not more than two regimens that included taxanes or anthracyclines as palliative therapy were eligible.
  • Patients were kept on therapy until disease progression, unacceptable toxicity or patient refusal.
  • The policy of dose adjustments based on the intercycle peaks of bilirubin and alkaline phosphatase appears to have a positive impact in the therapeutic index of trabectedin.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Breast Neoplasms / drug therapy. Dioxoles / therapeutic use. Isoquinolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Tetrahydroisoquinolines

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1256-65 [11230466.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4725-32 [11156226.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):814-23 [15897246.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Nov;12(11):1843-53 [14585059.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] Mol Cancer Ther. 2002 Dec;1(14):1327-34 [12516966.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6909-15 [12460906.001]
  • [Cites] Oncologist. 2002;7(3):210-6 [12065793.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • (PMID = 16736024.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  • [Other-IDs] NLM/ PMC2361304
  •  go-up   go-down


33. Hammond LA, Eckardt JR, Kuhn JG, Gerson SL, Johnson T, Smith L, Drengler RL, Campbell E, Weiss GR, Von Hoff DD, Rowinsky EK: A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res; 2004 Mar 1;10(5):1645-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
  • The feasibility of administering various sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TEM) in patients with advanced solid neoplasms was evaluated in this Phase I and pharmacological study to assess this premise in the clinical setting.
  • EXPERIMENTAL DESIGN: Sixty-three patients were randomized to receive treatment with oral TEM daily on days 1-5 and BCNU administered i.v., either on day 1 before TEM [Sequence (Seq) B-->T] or day 5 after TEM (Seq T-->B).
  • Treatment was repeated every 6 weeks.
  • Notable antitumor activity was observed in patients with glioblastoma multiforme, sarcoma, and ovarian carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / toxicity. Carmustine / toxicity. Dacarbazine / analogs & derivatives. Dacarbazine / toxicity. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Platelets / drug effects. Blood Platelets / pathology. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neutrophils / drug effects. Neutrophils / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15014015.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA54174; United States / NCI NIH HHS / CA / CA69853; United States / NCRR NIH HHS / RR / M01 RR01346
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; U68WG3173Y / Carmustine
  •  go-up   go-down


34. Sabbatini P, Rowand JL, Groy A, Korenchuk S, Liu Q, Atkins C, Dumble M, Yang J, Anderson K, Wilson BJ, Emmitte KA, Rabindran SK, Kumar R: Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res; 2009 May 1;15(9):3058-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Dysregulation of the insulin-like growth factor-I receptor (IGF-IR) signaling pathway has been implicated in the development of many types of tumors, including prostate, colon, breast, pancreatic, ovarian, and sarcomas.
  • Agents that inhibit IGF-IR activity may be useful in treatment of patients with various cancers.
  • It inhibits the proliferation of cell lines derived from solid and hematologic malignancies, with multiple myeloma and Ewing's sarcoma cell lines being most sensitive.
  • CONCLUSION: GSK1904529A is a promising candidate for therapeutic use in IGF-IR-dependent tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Imidazoles / pharmacology. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. Receptor, IGF Type 1 / antagonists & inhibitors
  • [MeSH-minor] 3-Hydroxybutyric Acid / metabolism. Animals. Apoptosis / drug effects. Blood Glucose / metabolism. Blotting, Western. Cell Cycle / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. Male. Mice. Mice, Nude. Neoplasms / drug therapy. Neoplasms / metabolism. Neoplasms / pathology. Phosphorylation / drug effects. Receptor, Insulin / antagonists & inhibitors. Receptor, Insulin / metabolism. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383820.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Glucose; 0 / GSK1904529A; 0 / Imidazoles; 0 / Protein Kinase Inhibitors; 0 / Pyridines; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptor, Insulin; TZP1275679 / 3-Hydroxybutyric Acid
  •  go-up   go-down


35. Dorr RT, Liddil JD, Sami SM, Remers W, Hersh EM, Alberts DS: Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anticancer Drugs; 2001 Mar;12(3):213-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In freshly isolated human tumors tested in soft agar, there was marked activity (mean IC50 in microg/ml) for AMP-53 in four cell types: breast cancer (0.09), lung cancer (0.06), renal cell carcinomas (0.06) and multiple myeloma (0.03).
  • Compound AMP-1 was shown to be superior to amonafide in the mammary 16C breast cancer model in B6CF31 mice, but it had little activity in Colon-38 nor in M5076 ovarian sarcomas in vivo.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Imides / pharmacology. Intercalating Agents / pharmacology. Isoquinolines / pharmacology. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Animals. Colony-Forming Units Assay. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Female. Humans. Male. Mice. Mice, Inbred C57BL. Mice, Nude. Naphthalimides. Neoplasms / drug therapy. Tumor Stem Cell Assay

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11290869.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 49875
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Imides; 0 / Intercalating Agents; 0 / Isoquinolines; 0 / Naphthalimides; 0 / azonafide; 1Q8D39N37L / amonafide
  •  go-up   go-down


36. Suzuki K, Yano T, Sadzuka Y, Sugiyama T, Seki T, Asano R: Restoration of connexin 43 by Bowman-Birk protease inhibitor in M5076 bearing mice. Oncol Rep; 2005 Jun;13(6):1247-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was designed to investigate the effects of Bowman-Birk inhibitor (BBI) on up-regulation of connexin (Cx) expression to estimate BBI's tumor-suppressor effect in mice with M5076 ovarian sarcoma.
  • Therefore, it suggests that the anti-carcinogenic effects of BBI induced negative growth control caused by the expression of Cx43 genes in mice with M5076 ovarian sarcoma.
  • [MeSH-major] Connexin 43 / metabolism. Ovarian Neoplasms / drug therapy. Sarcoma, Experimental / drug therapy. Trypsin Inhibitor, Bowman-Birk Soybean / therapeutic use. Trypsin Inhibitors / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870950.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Connexin 43; 0 / Proliferating Cell Nuclear Antigen; 0 / Trypsin Inhibitor, Bowman-Birk Soybean; 0 / Trypsin Inhibitors
  •  go-up   go-down


37. Nagasawa K, Nagai K, Ohnishi N, Yokoyama T, Fujimoto S: Contribution of specific transport systems to anthracycline transport in tumor and normal cells. Curr Drug Metab; 2001 Dec;2(4):355-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to minimize their adverse effects in clinical cancer chemotherapy, anthracyclines must be selectively transported into tumor cells.
  • In human cultured leukemia HL60 cells, as tumor cells, and human fresh mononuclear cells, as normal cells, doxorubicin, pirarubicin, daunorubicin and idarubicin were incorporated via a common carrier-mediated system, but the carriers were different in the two cell types.
  • In HL60 cells, it was indicated that a nucleoside transport system contributed, at least in part, to the transport of doxorubicin and pirarubicin, but not daunorubicin and idarubicin, and its contribution to pirarubicin transport was found in other tumor cells, i.e. mouse ovarian sarcoma M5076 and Ehrlich ascites carcinoma cells.
  • [MeSH-major] Anthracyclines / metabolism. Biological Transport / physiology. Leukocytes, Mononuclear / drug effects. Tumor Cells, Cultured
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Dose-Response Relationship, Drug. HL-60 Cells / drug effects. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11766987.001).
  • [ISSN] 1389-2002
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents
  • [Number-of-references] 85
  •  go-up   go-down


38. Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA: Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol; 2009 Jun;64(1):53-65
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Voreloxin, formerly known as SNS-595 or AG-7352, is a novel naphthyridine analog currently under investigation for the treatment of ovarian and hematologic malignancies.
  • METHODS: The cytotoxicity of voreloxin in vitro was examined by MTT assay in 15 cell lines, including 4 drug-resistant lines.
  • Tumors were allowed to grow to approximately 150 mm(3) prior to treatment with voreloxin or comparator drugs.
  • Similar activity was observed in vitro in drug-resistant cell lines, including those that overexpress P-glycoprotein and have reduced topoisomerase levels.
  • Voreloxin demonstrated strong dose-dependent tumor growth inhibition (63-88%) in 10 of 11 solid tumor (breast, ovarian, colon, lung, gastric, and melanoma) xenograft models, 2 hematologic tumor xenograft models, 3 multidrug resistant tumor models and 3 murine syngeneic tumor models (Colon 26, Lewis Lung carcinoma, M5076 Ovarian Sarcoma).
  • CONCLUSIONS: These data demonstrate that voreloxin is a broadly active anti-tumor agent in vitro and in vivo, with potent activity in aggressive and drug-resistant tumor models.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Caspase 3 / drug effects. Naphthyridines / pharmacology. Neoplasms / drug therapy. Thiazoles / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Female. Humans. Immunohistochemistry. Inhibitory Concentration 50. Mice. Mice, Inbred BALB C. Mice, Nude. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931998.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Naphthyridines; 0 / Thiazoles; EC 3.4.22.- / Caspase 3; K6A90IIZ19 / vosaroxin
  •  go-up   go-down


39. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res; 2005 Apr 15;11(8):2785-808
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
  • 2-[(18)F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamental property of neoplasia, the Warburg effect.
  • However, because it accurately detects recurrent or residual disease, FDG-PET also has significant potential for assessing therapy response.
  • In this regard, it can improve patient management by identifying responders early, before tumor size is reduced; nonresponders could discontinue futile therapy.
  • Moreover, a reduction in the FDG-PET signal within days or weeks of initiating therapy (e.g., in lymphoma, non-small cell lung, and esophageal cancer) significantly correlates with prolonged survival and other clinical end points now used in drug approvals.
  • These findings suggest that FDG-PET could facilitate drug development as an early surrogate of clinical benefit.
  • Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed.
  • Recommendations include initial validation against approved therapies, retrospective analyses to define the magnitude of change indicative of response, further prospective validation as a surrogate of clinical benefit, and application as a phase II/III trial end point to accelerate evaluation and approval of novel regimens and therapies.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837727.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 274
  •  go-up   go-down






Advertisement